Related Experiment Videos
Use of bromocriptine in unexplained infertility
Clinical Reproduction and Fertility
|June 1, 1982
Summary
This study investigated bromocriptine for unexplained infertility. Results showed bromocriptine (a prolactin inhibitor) did not improve pregnancy rates compared to placebo in regularly ovulating women.
Area of Science:
- Reproductive Endocrinology
- Clinical Pharmacology
Background:
- Unexplained infertility affects a significant number of couples.
- Bromocriptine is a dopamine agonist used to lower prolactin levels.
- Its efficacy in non-hyperprolactinemic infertility requires investigation.
Purpose of the Study:
- To evaluate the effectiveness of bromocriptine therapy in infertile patients with unexplained etiology.
- To compare bromocriptine treatment against placebo in a double-blind trial.
Main Methods:
- A double-blind, placebo-controlled trial involving 50 regularly ovulating infertile patients.
- Baseline hormonal assessments (estrogen, pregnanediol, prolactin, hCG) were conducted.
- Patients received either bromocriptine or placebo for three cycles, followed by cross-over therapy if conception did not occur.
Main Results:
- Overall, 36% of patients conceived during the study period.
- The pregnancy rate during bromocriptine treatment was not significantly different from the placebo group.
- Conception occurred during observation, bromocriptine, placebo, and follow-up periods.
Conclusions:
- Bromocriptine therapy did not demonstrate a superior pregnancy rate compared to placebo in regularly ovulating infertile patients.
- Further research may be needed to identify specific subgroups that could benefit from bromocriptine.